trending Market Intelligence /marketintelligence/en/news-insights/trending/kvttdvtaHkH3N8eGal8Bcw2 content esgSubNav
In This List

US court upholds insider trading lawsuit against Valeant, investor Ackman

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


US court upholds insider trading lawsuit against Valeant, investor Ackman

A U.S. District court tentatively denied a request by Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to dismiss claims of insider trading by Allergan Inc.'s shareholders, Bloomberg News reported.

The shareholders of Allergan Inc., which is a part of Allergan plc, alleged that Ackman bought their shares while he secretly knew that Valeant was planning a hostile bid.

Judge David Carter of the U.S. District Court, Central District of California, Santa Ana, issued the tentative ruling and the defendants will likely face a jury trial in January 2018, the news outlet reported.

According to Bloomberg News, the case depends on whether in 2014, Ackman's Pershing Square Capital Management and Valeant planned to take their offer directly to the Botox maker's shareholders instead of negotiating a deal with management.

The case also depends on whether Pershing Square's efforts to buy Allergan were genuine or if it was just helping to make Valeant's bid easier, Bloomberg News reported.